{"protocolSection": {"identificationModule": {"nctId": "NCT01332071", "orgStudyIdInfo": {"id": "114040"}, "organization": {"fullName": "GlaxoSmithKline", "class": "INDUSTRY"}, "briefTitle": "Avandamet Bioequivalence Study Brazil - Fed Administration", "officialTitle": "Assessment of Relative Bioavailability of Avandamet 4 mg + 1000 mg (GSK) in the Form of Film Coated Tablets Versus Avandamet 2 mg + 500 mg (GSK) in the Form of Film Coated Tablets, in Healthy Volunteers After Feeding Standardized, Using Liquid Chromatography."}, "statusModule": {"statusVerifiedDate": "2017-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-11-24", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2009-12-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-12-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-08-31", "studyFirstSubmitQcDate": "2011-03-17", "studyFirstPostDateStruct": {"date": "2011-04-08", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-03-17", "resultsFirstSubmitQcDate": "2011-03-17", "resultsFirstPostDateStruct": {"date": "2011-04-08", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-06-14", "lastUpdatePostDateStruct": {"date": "2017-07-12", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GlaxoSmithKline", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The study is prospective, open-label, randomized, crossover, with 02 treatments, 02 sequences, and 02 periods. The volunteers received, in each period, the reference or the test formulation after standardized meals.", "detailedDescription": "This is an open-label, randomized, crossover study with 02 treatments, 02 sequences, and 02 periods, in which the healthy volunteers received, in each period, the test or the reference formulation after standardized meals. Test product is Rosiglitazone Maleate + Metformin - Avandamet 4 mg + 1000 mg (GlaxoSmithKline Brasil Ltda) in the form of film coated tablets. Reference product is Rosiglitazone Maleate + Metformin - Avandamet 2 mg + 500 mg (Glaxo Smith Kline Brasil Ltda) in the form of film coated tablets. The population is composed by 26 healthy volunteers, adults, of both genders and their ages varied between 18 and 50 years. Their body mass index (BMI) varied between 18,5 and 25. There are no restrictions regarding the ethnic group. The relative bioavailability of the two formulations, after oral administration, will be evaluated based on statistical comparisons of relevant pharmacokinetic parameters obtained from data of drug concentration in blood."}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 2"], "keywords": ["Metformin", "Rosiglitazone", "Healthy volunteers", "Avandamet", "Fed conditions", "Bioequivalence"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "OTHER", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 26, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Avandamet test product", "type": "ACTIVE_COMPARATOR", "description": "Test product: Avandamet (Rosiglitazone Maleate + Metformin) 4 miligrams (mg) + 1000 mg in Period 1, followed by a 7-day washout period during which no medication was administered, followed by reference product: Avandamet (Rosiglitazone Maleate + Metformin) 2 mg + 500 mg in Period 2", "interventionNames": ["Drug: Rosiglitazone Maleate + Metformin 4 miligrams (mg) + 1000 mg"]}, {"label": "Avandamet reference product", "type": "ACTIVE_COMPARATOR", "description": "Reference product: Avandamet (Rosiglitazone Maleate + Metformin) 2 miligrams (mg) + 500 mg in Period 1; followed by a 7-day washout period during which no medication was administered; followed by test product: Avandamet (Rosiglitazone Maleate + Metformin) 4 mg + 1000 mg in Period 2", "interventionNames": ["Drug: Rosiglitazone Maleate + Metformin 2 miligrams (mg) + 500 mg"]}], "interventions": [{"type": "DRUG", "name": "Rosiglitazone Maleate + Metformin 2 miligrams (mg) + 500 mg", "description": "Avandamet reference product", "armGroupLabels": ["Avandamet reference product"]}, {"type": "DRUG", "name": "Rosiglitazone Maleate + Metformin 4 miligrams (mg) + 1000 mg", "description": "Avandamet test product", "armGroupLabels": ["Avandamet test product"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "AUC0-t of Rosiglitazone Maleate", "description": "The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC 0-t is calculated from time 0 (prior to administration of medication) to time t (the time of the last quantifiable concentration). The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. ng, nanograms; ml, milliliter.", "timeFrame": "Day 1 (day that blood collection started) and Day 2 (Period 1) and Days 8 and 9 (Period 2)"}, {"measure": "Cmax of Rosiglitazone Maleate", "description": "Cmax is defined as the maximum or \"peak\" concentration of a drug observed after its administration. Cmax is one of the parameters of particular use in estimating the bioavailability of drugs, by measuring the total amount of drug absorbed.", "timeFrame": "Day 1 (day that blood collection started) and Day 2 (Period 1) and Days 8 and 9 (Period 2)"}, {"measure": "AUC0-infinity of Rosiglitazone Maleate", "description": "The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC0-infinity is calculated from time 0 (prior to administration of medication) to infinity (the time of complete elimination of the drug). The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption.", "timeFrame": "Day 1 (day that blood collection started) and Day 2 (Period 1) and Days 8 and 9 (Period 2)"}, {"measure": "AUC0-t of Metformin Hydrochloride", "description": "The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC0-t is calculated from time 0 (prior to administration of medication) to time t (the time of the last quantifiable concentration). The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. ng, nanograms; ml, milliliter.", "timeFrame": "Day 1 (day that blood collection started) and Day 2 (Period 1) and Days 8 and 9 (Period 2)"}, {"measure": "AUC0-infinity of Metformin Hydrochloride", "description": "The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC0-infinity is calculated from time 0 (prior to administration of medication) to infinity (the time of complete elimination of the drug). The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption.", "timeFrame": "Day 1 (day that blood collection started) and Day 2 (Period 1) and Days 8 and 9 (Period 2)"}, {"measure": "Cmax of Metformin Hydrochloride", "description": "Cmax is defined as the maximum or \"peak\" concentration of a drug observed after its administration. Cmax is one of the parameters of particular use in estimating the bioavailability of drugs, by measuring the total amount of drug absorbed.", "timeFrame": "Day 1 (day that blood collection started) and Day 2 (Period 1) and Days 8 and 9 (Period 2)"}]}, "eligibilityModule": {"eligibilityCriteria": "EXCLUSION CRITERIA:\n\n* The volunteer has a known hypersensitivity to the study drug or to compounds chemically related;\n* History or presence of hepatic or gastrointestinal illnesses, or other condition that interferes over the drug's absorption, distribution, excretion or metabolism;\n* History of neurological, endocrine, pulmonary, hamatologic, immune, brain, metabolic or cardiovascular illness;\n* Hypo or hypertension of any etiologic that needs pharmacologic treatment;\n* The results of the laboratory exams are out of the values considered as normal according this protocol's rules, unless that they are considered as clinically irrelevant by the investigator;\n* Has history of alcohol or drugs abuse;\n* History of use drug inducing and/or inhibitors of hepatic metabolism within 30 days prior to drug study administration;\n* Use of MAO inhibitors two weeks before the start of treatment; - Use of inhibitors of 5-TH reuptake,\n* Pregnancy or breastfeeding,\n* Smoking;\n* Use of regular medication within 4 weeks prior to study iniciation;\n* Use of experimental drug or participation in any clinical study within 6 months prior to study iniciation.\n\nINCLUSION CRITERIA:\n\n* Age between 18 and 50 years;\n* Body mass index \u2265 18,5 and \u226425,0, can vary up to 15% for the upper limit (18,5 to 28,75);\n* Good health conditions;\n* Obtain the Informed Consent's signed.", "healthyVolunteers": true, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "50 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "GSK Clinical Trials", "affiliation": "GlaxoSmithKline", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "GSK Investigational Site", "city": "Goiania", "state": "Goi\u00e1s", "country": "Brazil", "geoPoint": {"lat": -16.67861, "lon": -49.25389}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Test Product in Period 1; Reference Product in Period 2", "description": "Test product: Rosiglitazone Maleate + Metformin film coated tablets (Avandamet) 4 milligrams (mg) + 1000 mg (GlaxoSmithKline Brasil Ltda) in Period 1; followed by a 7-day washout period during which no medication was administered; followed by reference product: Avandamet 2 mg + 500 mg (GlaxoSmithKline Brasil Ltda) in Period 2"}, {"id": "FG001", "title": "Reference Product in Period 1; Test Product in Period 2", "description": "Reference product: Avandamet 2 mg + 500 mg in Period 1; followed by a 7-day washout period during which no medication was administered; followed by test product: Avandamet 4 mg + 1000 mg in Period 2"}], "periods": [{"title": "Period 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "13"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "13"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "7-Day Washout Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "13"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "13"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Period 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "13"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "13"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Participants Receiving Both Test and Reference Product", "description": "Participants receiving either test product: Avandamet 4 mg + 1000 mg in Period 1; followed by reference product: Avandamet 2 mg + 500 mg in Period 2 or reference product in Period 1 and test product in Period 2"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "26"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "29.77", "spread": "6.80"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "13"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "13"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "AUC0-t of Rosiglitazone Maleate", "description": "The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC 0-t is calculated from time 0 (prior to administration of medication) to time t (the time of the last quantifiable concentration). The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. ng, nanograms; ml, milliliter.", "populationDescription": "Participants who completed the study", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng per hour per ml (ng.h/ml)", "timeFrame": "Day 1 (day that blood collection started) and Day 2 (Period 1) and Days 8 and 9 (Period 2)", "groups": [{"id": "OG000", "title": "Test Product", "description": "Test product: Rosiglitazone Maleate 4 mg in both periods"}, {"id": "OG001", "title": "Reference Product", "description": "Reference product: Rosiglitazone Maleate 2 mg in both periods"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "26"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1731.22", "spread": "510.47"}, {"groupId": "OG001", "value": "1770.93", "spread": "469.14"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "This is a bioequivalence study. The study was performed to fulfill a specific regulatory demand of the Brazilian Regulatory Agency - ANVISA, in order to register a new dosage of medication.", "paramType": "Ratio T formulation/R formulation", "paramValue": "96.58", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "93.44", "ciUpperLimit": "99.83", "estimateComment": "The ratio between the geometric means of the test (T) and reference (R) formulations was calculated."}]}, {"type": "PRIMARY", "title": "Cmax of Rosiglitazone Maleate", "description": "Cmax is defined as the maximum or \"peak\" concentration of a drug observed after its administration. Cmax is one of the parameters of particular use in estimating the bioavailability of drugs, by measuring the total amount of drug absorbed.", "populationDescription": "Participants who completed the study", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/ml", "timeFrame": "Day 1 (day that blood collection started) and Day 2 (Period 1) and Days 8 and 9 (Period 2)", "groups": [{"id": "OG000", "title": "Test Product", "description": "Test product: Rosiglitazone Maleate 4 mg in both periods"}, {"id": "OG001", "title": "Reference Product", "description": "Reference product: Rosiglitazone Maleate 2 mg in both periods"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "26"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "265.45", "spread": "44.33"}, {"groupId": "OG001", "value": "270.97", "spread": "48.32"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "This is a bioequivalence study. The study was performed to fulfill a specific regulatory demand of the Brazilian Regulatory Agency - ANVISA, in order to register a new dosage of medication.", "paramType": "Ratio T formulation/R formulation", "paramValue": "97.76", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "93.25", "ciUpperLimit": "102.50", "estimateComment": "The ratios between the geometric means of the test (T) and reference (R) formulations was calculated."}]}, {"type": "PRIMARY", "title": "AUC0-infinity of Rosiglitazone Maleate", "description": "The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC0-infinity is calculated from time 0 (prior to administration of medication) to infinity (the time of complete elimination of the drug). The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption.", "populationDescription": "Participants who completed the study", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng.h/ml", "timeFrame": "Day 1 (day that blood collection started) and Day 2 (Period 1) and Days 8 and 9 (Period 2)", "groups": [{"id": "OG000", "title": "Test Product", "description": "Test product: Rosiglitazone Maleate 4 mg in both periods"}, {"id": "OG001", "title": "Reference Product", "description": "Reference product: Rosiglitazone Maleate 2 mg in both periods"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "26"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1776.28", "spread": "519.63"}, {"groupId": "OG001", "value": "1825.35", "spread": "494.35"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "This is a bioequivalence study. The study was performed to fulfill a specific regulatory demand of the Brazilian Regulatory Agency - ANVISA, in order to register a new dosage of medication.", "paramType": "Ratio T formulation/R formulation", "paramValue": "96.47", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "93.32", "ciUpperLimit": "99.72", "estimateComment": "The ratio between the geometric means of the test (T) and reference (R) formulations was calculated."}]}, {"type": "PRIMARY", "title": "AUC0-t of Metformin Hydrochloride", "description": "The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC0-t is calculated from time 0 (prior to administration of medication) to time t (the time of the last quantifiable concentration). The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. ng, nanograms; ml, milliliter.", "populationDescription": "Participants who completed the study", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng.h/ml", "timeFrame": "Day 1 (day that blood collection started) and Day 2 (Period 1) and Days 8 and 9 (Period 2)", "groups": [{"id": "OG000", "title": "Test Product", "description": "Test product: Metformin Hydrochloride 1000 mg in both periods"}, {"id": "OG001", "title": "Reference Product", "description": "Reference product: Metformin Hydrochloride 500 mg in both periods"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "26"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9623.4", "spread": "2175.4"}, {"groupId": "OG001", "value": "10074.4", "spread": "2411.7"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "This is a bioequivalence study. The study was performed to fulfill a specific regulatory demand of the Brazilian Regulatory Agency - ANVISA, in order to register a new dosage of medication.", "paramType": "Ratio T formulation/R formulation", "paramValue": "95.79", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "91.67", "ciUpperLimit": "100.10", "estimateComment": "The ratios between the geometric means of the test (T) and reference (R) formulations was calculated."}]}, {"type": "PRIMARY", "title": "AUC0-infinity of Metformin Hydrochloride", "description": "The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC0-infinity is calculated from time 0 (prior to administration of medication) to infinity (the time of complete elimination of the drug). The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption.", "populationDescription": "Participants who completed the study", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng.h/ml", "timeFrame": "Day 1 (day that blood collection started) and Day 2 (Period 1) and Days 8 and 9 (Period 2)", "groups": [{"id": "OG000", "title": "Test Product", "description": "Test product: Metformin Hydrochloride 1000 mg in both periods"}, {"id": "OG001", "title": "Reference Product", "description": "Reference product: Metformin Hydrochloride 500 mg in both periods"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "26"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10419.8", "spread": "2198.2"}, {"groupId": "OG001", "value": "11063.7", "spread": "2798.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "This is a bioequivalence study. The study was performed to fulfill a specific regulatory demand of the Brazilian Regulatory Agency - ANVISA, in order to register a new dosage of medication.", "paramType": "Ratio T formulation/R formulation", "paramValue": "94.86", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "90.70", "ciUpperLimit": "99.22", "estimateComment": "The ratios between the geometric means of the test (T) and reference (R) formulations was calculated."}]}, {"type": "PRIMARY", "title": "Cmax of Metformin Hydrochloride", "description": "Cmax is defined as the maximum or \"peak\" concentration of a drug observed after its administration. Cmax is one of the parameters of particular use in estimating the bioavailability of drugs, by measuring the total amount of drug absorbed.", "populationDescription": "Participants who completed the study", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/ml", "timeFrame": "Day 1 (day that blood collection started) and Day 2 (Period 1) and Days 8 and 9 (Period 2)", "groups": [{"id": "OG000", "title": "Test Product", "description": "Test product: Metformin Hydrochloride 1000 mg in both periods"}, {"id": "OG001", "title": "Reference Product", "description": "Reference product: Metformin Hydrochloride 500 mg in both periods"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "26"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1623.6", "spread": "326.5"}, {"groupId": "OG001", "value": "1663.9", "spread": "370.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "This is a bioequivalence study. The study was performed to fulfill a specific regulatory demand of the Brazilian Regulatory Agency - ANVISA, in order to register a new dosage of medication.", "paramType": "Ratio T formulation/R formulation", "paramValue": "97.88", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "93.15", "ciUpperLimit": "102.86", "estimateComment": "The ratios between the geometric means of the test (T) and reference (R) formulations was calculated."}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Test Product in Period 1; Reference Product in Period 2", "description": "Test product: Rosiglitazone Maleate + Metformin film coated tablets (Avandamet) 4 milligrams (mg) + 1000 mg (GlaxoSmithKline Brasil Ltda) in Period 1; followed by a 7-day washout period during which no medication was administered; followed by reference product: Avandamet 2 mg + 500 mg (GlaxoSmithKline Brasil Ltda) in Period 2", "seriousNumAffected": 0, "seriousNumAtRisk": 13, "otherNumAffected": 13, "otherNumAtRisk": 13}, {"id": "EG001", "title": "Reference Product in Period 1; Test Product in Period 2", "description": "Reference product: Avandamet 2 mg + 500 mg in Period 1; followed by a 7-day washout period during which no medication was administered; followed by test product: Avandamet 4 mg + 1000 mg in Period 2", "seriousNumAffected": 0, "seriousNumAtRisk": 13, "otherNumAffected": 13, "otherNumAtRisk": 13}], "otherEvents": [{"term": "Cephalea", "organSystem": "General disorders", "sourceVocabulary": "ds Navigator", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 13}]}, {"term": "Tension cephalea", "organSystem": "General disorders", "sourceVocabulary": "ds Navigator", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 13}]}, {"term": "Frontal cephalea", "organSystem": "General disorders", "sourceVocabulary": "ds Navigator", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 13}]}, {"term": "Diarrhea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "ds Navigator", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 13}]}, {"term": "Diarrhea with semi liquid stool", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "ds Navigator", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 13}]}, {"term": "Evacuation of liquid stool", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "ds Navigator", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 13}]}, {"term": "Post-study increased urea", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "ds Navigator", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 13}]}, {"term": "Post-study altered urine exam", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "ds Navigator", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 13}]}, {"term": "Post-study increased leucocytes", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "ds Navigator", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 13}]}, {"term": "Post-study increased total cholesterol", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "ds Navigator", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 13}]}, {"term": "Post-study increased triglycerides", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "ds Navigator", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 13}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "GSK Response Center", "organization": "GlaxoSmithKline", "phone": "866-435-7343"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000077154", "term": "Rosiglitazone"}, {"id": "C000030272", "term": "Maleic acid"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M245808", "name": "Maleic acid", "asFound": "Fast", "relevance": "HIGH"}, {"id": "M1677", "name": "Rosiglitazone", "asFound": "Facility", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}